Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Short squeeze not now but it will come for sure and then it could be a multi bagger in few days $
LOL! Today is a very glad day for all the CGIX shareholders --- 1:30 ideal R/S today! I bet the price will soon boost to Multi-dollars again due to coming merger news and more transition news ...
I always encouraged all the CGIX shareholders many times regarding the coming weeks! However a lots of CGIXers follow my advice to hold all the shares before todays R/S!
Hopefully it could find some temporary stop at the New Bottom$3.50, that some investors can buy in before the ultimate run occurs!
Monday CGIX should test $3.50/4.00 range and may climb because of short covering to $10.xx ++ directly...
Why not buying low risky CGIX shares after the 1:30 ideal R/S? $$$
Be honest $ RS is 1000 times better than delisting. With only 2 m OS and 6 m in cash this is a steal. Now merger could take place $ bullish
This week 1.00 $ would be nice! Bullish
$CGIX more news like merger soon to be announced $
Additionally, Mr. Roberts stated, “We are now focused on collecting cash that is due to the Company, substantially reducing our accounts payable with our unsecured creditors, focusing on the operational elements of our Discovery Services business, and continuing to explore strategic options, which could include the sale of other assets, a merger, reverse merger or other strategic transactions. With these asset sales now completed, we believe the Company is in a good position to explore further strategic initiatives as well as to grow the remaining Discovery Services business.”
Value investor please post news on topic
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners
Source: GlobeNewswire Inc.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Company’s July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX). The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019. Approximately $6 million of the second tranche financing is being used to pay down a note due to Cancer Genetics, subject to related contractual adjustments, in connection with the acquisition.
“We are excited to strengthen our partnership with Ampersand and to reinforce it through overwhelming support from our shareholders as we received approval for the second tranche financing”, stated Jack Stover, President & CEO of Interpace. He continued, “Ampersand is considered one of the leading private equity firms in the laboratory services space and the addition of the biopharma asset propels Interpace to the next level.”
About Interpace
Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Interpace’s Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX® that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN® for Barrett’s Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN® to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.
Interpace’s Biopharma Business provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.
For more information, please visit Interpace’s website at www.interpacediagnostics.com.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to the fact that there is no assurance the acquisition of the BioPharma business of Cancer Genetics, Inc. will be successfully integrated with the Company, or that the potential benefits of the acquisition, including future revenues, will be successfully realized. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company's most recent Annual Report on Form 10-K, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts:
Investor Relations
Edison Group
Joseph Green
(646) 653-7030
jgreen@edisongroup.com
Primary Logo
CGIX $ beautiful chart in progess $ Hope for clay’s update soon. This has unbelievable potential! Slowly and steady but huge breakout is imminent.
True my friend!
Keep calm, bulls are in full control here! Enjoy today, but next week .20 is history $$$
We are ob a steady rise. Not to late for all. This will climb very high in october wide above expectations. RSI not in power zone yet!
20c is history soon!
Already climbed to .15 AH! Holds its baseline. Some people missed the CGIX-Train. The best is yet to come.
Big things coming! One of the hottest merger plays $
the vote is Oct 10 to approve the 7.7 million $ next week this runs $
"Under the terms of the acquisition agreement, Interpace purchased the BioPharma Business pursuant to a Uniform Commercial Code Article 9 transaction whereby secured creditors were paid off and Interpace made an additional payment of approximately $4.5 million to Cancer Genetics, using proceeds from the initial financing provided by Ampersand. In addition, Interpace issued Cancer Genetics a $7.7 million 6% interest bearing note due upon the earlier of Interpace’s shareholder approval and Ampersand’s second tranche investment or three years."
Yes and more to come $$$
$cgix to new highs soon. EOD run would be nice
Gaining momentum $ Bullish
Sweet white candle! Waiting for merger news next days ...
$CGIX HUGE date 10/11 possible merger vote... Bullish
1.00 $ no RS needed. GO!
Heading up again $ news will be announced soon about merger deals!
I like clay’s analysis: “We made progress here”
?? WOW
No no no, no real direction $ i bet on the upside
Be careful... massive breakout SOON $$
Yes true, but it shows strength this time ... RSI upticking so could break .11 soon
In my opinion CGIX found nice base / support level above .10$ still totally undervalued
Wait, keep calm its no pos scam, simply higher highs and higher lows
Why is it so strong? Build nice support and momentum. Lots of room to run up through resistance. Merger news ob its way?
Volume is drying out... look for a spike soon...
toybaby feel the same. It was shorted in extremely way over a long period now with good news it could spike in other direction!
Beware of short position. CGIX could run-up strong this week into IDXG annual shareholder meeing vote. Should see substantial upward movement.
Chart and stochastics looking better and better from day to day. Massive breakout on the upside in the works ? Lots of potential. it remains exciting.
Maybe, but many Investors were short. If the price holds sideway there could be a big surprise. 200 K will be bought as a starter of the rally.
It‘s fighting to beat 10c++. If we break resistance this could run hard!
Hear that on another board... i found this:
$CGIX A friend of mine is extremely bullish on this position. I don't see really why. I noticed that management has been working diligently in finding value for share holders and they have Sold segments of their business.,Paid off some outstanding debt, and managed to put 3M in cash accounts. Their last Earnings statement they continued talking about merger possibility or partnerships. With that, what other catalyst is out there? All my friend says, load up Hankster, something Big is coming. Any idea what's referring to? Maybe he don't know anything and is just Hopeful.
Merger candidate?
Smell a breakout here ??
Low risk high reward possible .39++ soon